Terry Smith (@TerryMSmith) profile picture

Former scientist. Penn State PhD/MBA 2006. Professional small/mid cap biotech investor.

Joined January 2010
Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)Photo by Terry Smith (@TerryMSmith)
Terry Smith retweeted
Replying to @silvertrade
I hate to even comment on such a serious thing because only the safety of people matters, but FWIW I asked Teva’s CEO about their operations in Israel earlier this month and he said Israel is less than 8% of their manufacturing. biotechtv.com/post/teva-marc…
4
2
21
4,840
Excellent report from Furey research partners. Small cap managers are getting crushed by the outperformance in biotech where they seem to be chronically under-exposed.
1
2
452
Wow. Interesting use of Twitter by Dr. Makary
This Post is from an account that no longer exists. Learn more
2
1,086
All those companies waiting to submit their NDA until Rare Disease Day just wasted two months.
Replying to @FDA
@US_FDA @NIH Rare Disease Day, which was postponed in late February, now officially cancelled "due to ongoing logistical and timing challenges"
3
882
Would love to see 75 more of these
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
6
879
Acadia Pharma announced sale of their PRV for $150M. Ipsen got $158M for one in August. Previously the market had been around $100M.
1
5
3,084
I'm super late. Anyone worried that the PFS of 8 mos is based on 6 patients at risk with lots of censors at 2-3 mos? It seems they counted unconfirmed responders who are still on drug as responders? I calc ORR on the first 61 pts at 26% and ORR on the next 36 as 11%. Right? $RVMD
9
1,829
Wow, X has informed me that I have been on X for 14 years. For some reason it doesn’t seem that long! #MyXAnniversary
1
6
1,185
Excellent results of acoramidis for #ATTR CM in ATTRIBUTE trial, just presented at #ESCCongress @secardiologia @seccCFyGenetCV @UnidadTtr
9
1
30
15,837
I was able to log in a couple minutes later. I bet some people dropped off when they said they aren't talking about price and can't say more about Biogen's commitment.
3
480
First quarter of launch Daybue sales $21-$23M. Guide to $45-55M next Q. Consensus was $2.5M and $7.2M, respectively. $ACAD
1
6
2
21
7,703
Pipeline herding in drug development - In 2000, there were on avg 3 assets/target In 2022, there are on avg 7 assets/target (in oncology its 9 assets/target) nature.com/articles/d41573-0…
3
29
5
118
42,929
Oncology is 37% of the entire biopharma pipeline.
FDA is issuing new draft guidance, "Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics," per Fed Register Public Inspection notice. I don't think the doc is up yet but it should post here fda.gov/regulatory-informati… FR notice public-inspection.federalreg…
1
7
3,102
Wow. FDA's top cell and gene therapy official is stepping down. It's a critical time for CGTs at FDA, with the division about to start a hiring spree and OTAT getting a recent reorganization (to the Office of Therapeutic Products).
Director of @FDACBER OTAT Wilson Bryan is retiring. He will leave by the end of March. Big loss for the cell and gene therapy divisions at the agency. #pharma
3
2
2,671
Is there anything stopping a hedge fund from filing another IPR on voclosporin? $AUPH
1
2
863
Got lots of Qs on my FOIA for #biotech post. So here's a 🧵on FOIA document content with an example:
1
2
2
42